Workflow
建发致新上市:新起点承载新梦想,聚力谱写发展新华章

Core Viewpoint - Jianfa Zhixin (建发致新) officially listed on the ChiNext board on September 25, marking its position as a leading national medical device distribution company in China. The company is experiencing rapid growth in revenue and profitability, driven by its strategic business expansion and innovative service offerings [1][2]. Group 1: Company Performance - Jianfa Zhixin is projected to achieve a revenue of 17.923 billion yuan in 2024, representing a year-on-year growth of 16.06%, with a net profit of 274 million yuan [1]. - From 2022 to 2024, the company’s revenue is expected to grow from 11.882 billion yuan to 17.923 billion yuan, with a compound annual growth rate (CAGR) of 22.81% [2]. - The net profit for the same period is forecasted to increase from 189 million yuan in 2022 to 274 million yuan in 2024, with a year-on-year growth of 20.68% in 2024, indicating improved profitability [2]. Group 2: Industry Landscape - The medical device market in China is expanding rapidly, with the market size projected to grow from 764.8 billion yuan in 2020 to 1,063.8 billion yuan in 2024, reflecting a CAGR of 8.60% [4]. - China has become the second-largest medical device market globally, following the United States, and is expected to maintain a favorable growth trajectory [4]. Group 3: Competitive Advantage - Jianfa Zhixin has established a strong position in the high-value medical device distribution sector, focusing on direct sales and distribution, as well as providing centralized operation services for medical consumables (SPD) [2][5]. - The company differentiates itself by leveraging modern technologies such as information management, IoT, and big data to enhance its service offerings and operational efficiency [5][6]. - Jianfa Zhixin aims to create a comprehensive medical device distribution hub that integrates channels, warehousing, logistics, and financial services, thereby improving the efficiency of the supply chain [5]. Group 4: Future Strategy - The company plans to utilize IPO proceeds for upgrading its information systems, enhancing SPD services, and supplementing working capital [7]. - Jianfa Zhixin intends to further explore opportunities in centralized operation management services for public hospitals and continue developing its SPD management system [7].